

FOR
EARNINGS RELEASE

IMMEDIATE

RELEASE

Date: November 12, 2020

Advanced Enzyme Technologies Limited announces Financial Results for Second Quarter and Half Year ended September 2020

Mumbai, India: Thursday, November 12, 2020 – Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for second quarter ended September 2020.

Financial Highlights – Q2FY21 vs Q2FY20:

- ✓ Consolidated Q2FY21 Sales up 8% Y-o-Y to INR 1,204 mn against INR 1,114 mn in Q2FY20
- ✓ Consolidated EBITDA for Q2FY21 stands at INR 585 mn against INR 473 mn in Q2FY20, up 24%
- ✓ Consolidated EBITDA Margin for Q2FY21 stands at 49% as against 42% in Q2FY20
- ✓ Consolidated Q2FY21 Net Profit rise by 21% at INR 386 mn against INR 318 mn in Q2FY20

Financial Highlights – H1FY21 vs H1FY20:

- ✓ Consolidated H1FY21 Sales up 4% Y-o-Y to INR 2,309 mn against INR 2,218 mn in H1FY20
- ✓ Consolidated EBITDA for H1FY21 stands at INR 1,102 mn against INR 1,008 mn in H1FY20, up 9%
- ✓ Consolidated EBITDA Margin for H1FY21 stands at 48% as against 45% in H1FY20
- ✓ Consolidated H1FY21 Net Profit rise by 11% at INR 734 mn against INR 658 mn in H1FY20

Results Conference Call Details

We will hold an earnings conference call on 12th November 2020, Thursday at 05:30 P.M. IST to discuss quarterly performance. Transcript of the call will be available later in the Investor Relations section of our website www.advancedenzymes.com

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: +91 22 6280 1403 / +91 22 7115 8304

Advanced Enzyme Technologies Ltd.

About Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited, incorporated in 1989, is a research driven company with global leadership in the manufacturing of enzymes. The company is committed to provide eco-safe solutions to wide variety of industries like human care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing, leather processing, paper & pulp processing, biofuels, biomass processing, bio catalysis, etc. The company aims to provide side-effect-free healthcare and eco-safe industrial solutions to its customers globally, and is today, the largest producer of enzymes in Central Asia.

Equipped with state-of-the-art 7 manufacturing facilities and 6 research & development locations across India, Germany and US, Advanced Enzymes exports to 45+ countries across 6 continents, and provides customized & effective enzyme solutions coupled with the best in technical advice & superior service.

Advanced Enzymes has received the Bio-Excellence award for being the Best Industrial Biotech Company at Bangalore India Bio in 2010 as well as 2014. In 2013, Advanced Enzymes has also been recognised by Inc. India, as one of the top 500 fastest-growing mid-sized companies in India. Advanced Enzymes has also been recipient of the Emerging India Award in 2010, in the Life Sciences category, by CNBC TV18 and ICICI Bank. Advanced Enzymes has also been awarded for Best IPO at IR Society Awards 2017, by Investor Relation Society of India in association with BSE, KPMG India and Bloomberg.

Forward-looking statements

This press release may contain forward-looking statements with respect to Advanced Enzyme Technologies' future (financial) performance and position. Such statements are based on current expectations, estimates and information currently available to the company.

Advanced Enzyme Technologies Limited cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. The company has no obligation to update the statements contained in this press release, unless required by law.